Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Chronic Obstructive Pulmonary Disease

Baird Chautauqua Fund Reports Q2 Lag After Tariff Whiplash, Highlights Diverging AI Chip Bets

Tariff headlines drove the quarter’s swings, prompting updates on AI chips, airlines, China exposure, plus biotech.

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets